title: Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis.
abstract: Since the first description of Cystic fibrosis (CF) more than 75 y ago, significant advances have been made in understanding its pathogenesis and in developing specific therapies. The pace of these developments was further accelerated after the discovery of CF gene in 1989 and since then, CF has been transformed from being a pediatric illness into a chronic life-limiting genetic disorder with survival up to the fourth decade. The development of mutation-specific therapies in the first decade of the 21st century has the potential to change the natural history of CF and has now ushered in the era of 'Precision Medicine'. The ability to revert the basic defect in CF by using Personalized Medicine approach based on each individual's genetic profile will serve as a model for other chronic disorders as well. This review highlights the recent advances in the field of CF research that have led to a paradigm shift in its management and outcomes.
authors.affiliation: Division of Pulmonary Medicine, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, 3901 Beaubien St, Detroit, MI, 48201, USA, lguglani@med.wayne.edu.
authors.forename: Lokesh
authors.initials: L
authors.lastname: Guglani
mesh_terms: D003550:Cystic Fibrosis / Q000235:genetics* / Q000628:therapy; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009154:Mutation
chemical_list: D019005:Cystic Fibrosis Transmembrane Conductance Regulator